Concepedia

Thomas A. Abrams

TA

65

Publications

5.7K

Citations

37

H-Index

2007

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Massachusetts General Hospital

Harvard University

Beth Israel Deaconess Medical Center

The University of Texas MD Anderson Cancer Center

Thomas A. Abrams is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer research.

ORCID

Top concepts

Publications per year

2007–2024

65

Publications

65

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Andrew X. Zhu, Dushyant V. Sahani, Dan G. Duda et al. · Journal of Clinical Oncology · 2009 · 473 citations · Full text

Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque et al. · New England Journal of Medicine · 2023 · 465 citations · Full text

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott et al. · Journal of the National Comprehensive Cancer Network · 2017 · 345 citations · Full text

, , +17

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

Andrew X. Zhu, Jeffrey A. Meyerhardt, Lawrence S. Blaszkowsky et al. · The Lancet Oncology · 2009 · 308 citations

, , +8

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

Brian M. Wolpin, Aram F. Hezel, Thomas A. Abrams et al. · Journal of Clinical Oncology · 2008 · 291 citations · Full text

Rows per page

1–5 of 65